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Abstract
Objective To examine the impact of providing rapid diagnostic tests for
malaria on fever management in private drug retail shops where most
poor rural people with fever present, with the aim of reducing current
massive overdiagnosis and overtreatment of malaria.
Design Cluster randomized trial of 24 clusters of shops.
Setting Dangme West, a poor rural district of Ghana.
Participants Shops and their clients, both adults and children.
Interventions Providing rapid diagnostic tests with realistic training.
Main outcome measures The primary outcome was the proportion of
clients testing negative for malaria by a double-read research blood slide
who received an artemisinin combination therapy or other antimalarial.
Secondary outcomes were use of antibiotics and antipyretics, and safety.
Results Of 4603 clients, 3424 (74.4%) tested negative by double-read
research slides. The proportion of slide-negative clients who received
any antimalarial was 590/1854 (32%) in the intervention arm and
1378/1570 (88%) in the control arm (adjusted risk ratio 0.41 (95% CI
0.29 to 0.58), P<0.0001). Treatment was in high agreement with rapid
diagnostic test result. Of those who were slide-positive, 690/787 (87.8%)
in the intervention arm and 347/392 (88.5%) in the control arm received
an artemisinin combination therapy (adjusted risk ratio 0.96 (0.84 to
1.09)). There was no evidence of antibiotics being substituted for
antimalarials. Overall, 1954/2641 (74%) clients in the intervention arm
and 539/1962 (27%) in the control arm received appropriate treatment
(adjusted risk ratio 2.39 (1.69 to 3.39), P<0.0001). No safety concerns
were identified.
Conclusions Most patients with fever in Africa present to the private
sector. In this trial, providing rapid diagnostic tests for malaria in the
private drug retail sector significantly reduced dispensing of antimalarials
to patients without malaria, did not reduce prescribing of antimalarials
to true malaria cases, and appeared safe. Rapid diagnostic tests should
be considered for the informal private drug retail sector.
Registration Clinicaltrials.gov NCT01907672
Introduction
Malaria remains one of the most common diagnoses in Africa,
and fever the commonest outpatient presentation, althoughmost
children and adults with fever present solely to the private drug
retail sector (shops) rather than formal health services. A serious
problem of over-prescription of antimalarials to patients without
malaria has been found across the continent.1 2 There has been
a major shift in emphasis on treatment of febrile illness in the
formal health sector in Africa that antimalarial treatment should
always be guided by parasitological testing.3 4 This has been
driven by several factors, including that a large proportion of
patients with fever are being given antimalarials when they have
other, potentially serious causes of infection which are being
missed,1-7 the waste of relatively expensive antimalarials on
patients without malaria, and that unnecessary antimicrobial
use helps drive drug resistance and exposes patients to
unnecessary side effects.2 As a result of these efforts,
overdiagnosis of malaria in the public sector is now falling
rapidly.
However, most children and adults with febrile illness, including
the poorest, are treated in the private drug retail sector in most
countries in Africa, including Ghana, even where public sector
treatment is free.8-16 Strengthening the use of diagnostic tests
for malaria in public health facilities therefore affects only a
minority of cases of over-prescription of antimalarials. In rural
areas in particular, most of the poorest often access antimalarials
through the private drug retail sector, largely because of the
transport cost and opportunity cost (things people could
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otherwise spend money on) of accessing healthcare.17-20 In
recognition of this, several schemes, including the Affordable
Medicines Facility for malaria have been deployed to ensure
that effective antimalarials are available through private outlets
that poorer patients use.21 22 These schemes have provided drugs,
but generally not diagnostic support, and poor targeting of
antimalarials is recognized as a major risk to these efforts.23
Reducing overtreatment of malaria in the private sector is
becoming increasingly important as the proportion of fevers
attributable to malaria reduces so the relative importance of
non-malaria causes increases.24 25
Rapid diagnostic tests for malaria are potentially usable in
peripheral private drug retail facilities. They are sensitive and
can be used with minimal training.26 In the formal public sector,
substituting these for clinical (non-test based) diagnosis in
peripheral settings without access to laboratories generally leads
to significantly better targeting of antimalarials and less
over-prescription, including in Ghana, provided it is linked to
training.20-31 For this reason, providing free or subsidized rapid
diagnostic tests has been strongly advocated by some to be
provided for use in the private drug retail sector including, in
the UK, the Public Accounts Committee of the House of
Commons and National Audit Office,16 but without a strong
evidence base that they can be used correctly. The scale of
subsidy this would require is substantial; it is estimated there
are 656 million fevers a year in African children aged 0-4 years
old alone, of which only a minority go to the public sector.25 It
would change the nature of healthcare provision in Africa,
making private providers diagnosticians, until now the preserve
of clinicians. The evidence base to support this significant policy
change is weak with little reliable data from Africa outside
observational studies, and some less encouraging data from the
very different setting of South East Asia.30 32
There are several reasons why a technology that works in the
formal public sector may not work for shops. The most obvious
is that, if they are used correctly, a major effect of rapid
diagnostic tests is likely to be to reduce over-prescription of
antimalarials, so the effect in the private drug retail sector could
be to reduce sales of a major item, for which there may be no
rational economic advantage to the seller. Conversely,
incorrectly used rapid diagnostic tests in untrained hands could
lead to true cases of malaria, a potentially fatal disease, not
being treated because of false negative readings. There are also
safety concerns around bloodborne viruses (hepatitis, HIV,
Ebola); sharps disposal is difficult and sharps reuse may have
some economic advantage to shopkeepers (risking clients).
Additionally, sharps risk to shopkeepers is non-trivial in a setting
where hepatitis B prevalence is often over 10% in blood
donors.33 34 Private sector providers have training, incentives,
backgrounds, and population served that are different from the
formal public sector, so extrapolating directly from public sector
data to the private sector is unwise.
This study set out to examine the impact of providing rapid
diagnostic tests on antimalarial and other prescribing in the most
commonly used part of the private drug retail sector in rural and
semi-rural Ghana, chemical shops. In particular, we
hypothesized that providing rapid diagnostic tests will reduce
overprescribing of antimalarials to clients with no malaria. We
also aimed to look at safety, both in terms of deaths or adverse
illness from missed malaria when rapid diagnostic tests are
introduced and the use of sharps. This is one of the first trials
of diagnostics in the private drug retail sector in Africa, and
specifically West Africa.
Methods
Study site and population
The trial was carried out in Dangme West, a rural district with
widespread poverty in Ghana with an estimated population of
142 633 in 2009 mid-year. The people live in scattered small
communities and are mostly subsistence farmers or fishermen.
Vehicular transport is unavailable in many parts of the district,
making access to formal care difficult. Health services are
organized around a three tier system at district level, with the
district hospital as the referral level, the health centre at
subdistrict level, and the Community Health and Planning and
Services (CHPS) compounds, which deliver close-to-client
services mostly at home, at community level. There is one
district hospital, three health centres, 13 CHPS compounds, and
five formal private health facilities. In addition, 56 chemical
shops and six pharmacies sell pharmaceutical products (fig 1⇓);
Licensed Chemical Sellers are the main outlet for antimalarials
in Ghana.. Earlier studies carried out in the district showed that
for presumed “malaria” in the household, the first action taken
is, in order of the most common: home treatment, chemical
shop, health centre, hospital, drug peddler, and traditional
healer.12-36 The study was conducted across both the high and
low transmission seasons.
Chemical sellers in Ghana are regulated by the Pharmacy
Council. To be eligible, a person must possess a minimum of
secondary school level qualification, with basic knowledge in
healthcare delivery being an advantage. Applicants attend
pre-licensing training, and the licenses are renewed annually.
The shops are legally allowed to retail over-the-counter
medicines to members of the public in communities that the
Pharmacy Council considers poor. The authorized medicines
include analgesics and antimalarials. The only antibiotic allowed
is co-trimoxazole.
Trial design
A cluster randomized trial design was used, with a cluster
defined as a community with at least one chemical shop. Twenty
four communities, with one to five shops per community, were
eligible for inclusion in the study. The trial was evaluated among
clients reporting to a participating chemical shop complaining
of fever or requesting an antimalarial medicine. Clients were
excluded if they were pregnant, <6 months old, had signs of
severe disease, a prescription from a health facility, or would
be in the district for less than 28 days. Assessments for eligibility
were carried out by the chemical sellers, who were trained to
do so. Clients with severe disease or who were pregnant were
referred to the nearest health centre or the district hospital by
the chemical seller.
An initial baseline study was carried out involving a census,
including Global Positioning System (GPS), of all chemical
shops to document the location of each shop and antimalarials
available. The results of the baseline informed the study design.
As part of formative research, focus group discussions were
held with community members and chemical sellers to find out
how acceptable the idea of chemical sellers testing for malaria
in shops was, to community members and the best way to
introduce the intervention.
The intervention
Shops in communities randomised to the control arm were
expected to dispensemedicines without test results as per current
practice, while those in the intervention arm carried out a test
for malaria using an rapid diagnostic test before dispensing any
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medication. In positive malaria tests, rapid diagnostic tests form
a coloured line in the test area. Tests generally take 15–20
minutes depending on the test kit. CareStart Malaria HRP2 (Pf)
rapid diagnostic test kits, which fulfil all the WHO assessment
criteria, were provided by the study team on a monthly basis
and were free of charge to chemical sellers and clients. The
study team carried out regular quality control procedures by
picking a random sample of test kits from the shop for testing
using standard positive blood samples. This was to ensure that
the rapid diagnostic test kits continued to perform optimally
under the storage conditions in the chemical shop.
All chemical sellers attended a three day training on malaria,
covering topics that included the antimalarial drug policy of
Ghana; causes, signs, and symptoms of malaria; signs of severe
disease and indications for referral; how to take a blood sample
and make a blood slide; blood safety and handling of sharps;
infection prevention procedures; and standard operating
procedures of the study. Sellers in the intervention arm attended
an additional day of training, covering how to carry out and
interpret rapid diagnostic tests for malaria and further
management of clients with a negative rapid diagnostic test
result. The training involved a demonstration by a laboratory
technologist followed by practice sessions by chemical sellers
on their colleagues. They practised how to take a blood sample
safely and also tested for malaria with a rapid diagnostic test.
Test kits, sharps bins, and documentation were introduced and
used during the training. Lecture sessions were interspersed
with group discussions, role plays, and individual exercises.
Assignments were marked and discussed in class. A minimum
of two attendants were trained per shop to ensure continuity of
service. After the training, all chemical sellers were provided
with reference charts for doses of artemisinin combination
therapies. Whenever a trained shop attendant resigned and was
replaced by a new one, training was carried out in the shop for
the new attendant.
Since Ghana was one of the phase one countries benefitting
from the Affordable Medicines Facility for malaria, subsidized
artemisinin combination therapy was available at the lowest
level of the private drug retail sector from mid-2011, and
chemical sellers were encouraged to use their regular source of
supply of antimalarials. Bins for disposal of sharps and a
certificate identifying the seller as a trained provider of malaria
testing were also provided. Fieldworkers and supervisors were
also trained separately in taking of blood samples and rapid
diagnostic tests and the standard operating procedures of the
study to enable them to provide technical support to the chemical
sellers.
Study outcomes
The primary outcome was the proportion of clients who tested
negative for malaria by a double-read research blood slide and
who received an artemisinin combination therapy or other
antimalarial. Secondary outcomes included treatment with
antibiotics by test outcome, treatment of patients with a negative
rapid diagnostic test result, treatment with other antimalarials
or alternative treatments, the operational sensitivity of the rapid
diagnostic tests used by chemical sellers against research slide
results, the safety of use of rapid diagnostic tests at community
level, and the impact on numbers of referrals to formal medical
care.
The presence of malaria was assessed through a blood slide,
which was prepared by health centre laboratory staff from a
blood sample taken by the chemical seller as part of the
consultation with the client regardless of study arm. Slides were
double-read in research laboratories, and discrepant slides were
re-read by a third and senior microscopist. Information on the
test results obtained, medications dispensed, and whether the
client was referred were documented by the seller on a form
designed specifically for the study. The accuracy of the records
of drugs dispensed was validated by conducting random checks
of the forms and through “mystery clients.”
The “mystery client” complained of symptoms for himself or
his child at home and submitted to a test when it was offered,
observing the procedure the chemical seller followed for later
documentation using a checklist. To ensure that chemical sellers
correctly conducted the rapid diagnostic tests and adhered to
safety and infection control procedures, direct observation of
interactions between chemical sellers and clients was carried
out by the study team using a checklist on a weekly basis during
the first month of evaluation and for a further week mid-way
through the trial in both arms.
In both arms clients were assessed for eligibility and requested
to provide written consent for participation in the study. Basic
demographic details were collected from all consenting clients,
and a blood sample was taken by the chemical seller for the
research slide. Detailed directions to the client’s home were
also collected for the purposes of follow-up. Chemical sellers
had access to the subsidized green leaf logo artemisinin
combination therapy from the open market via the Affordable
Medicines Facility for malaria. In the control arm, services were
provided to clients following usual practice without test results.
The chemical sellers collected a blood sample in a “microtainer”
for study testing but did not do rapid diagnostic test testing.
Control chemical sellers used the same client record form as
the intervention arm.
In the rapid diagnostic test arm consent provided by clients
included consent for rapid diagnostic testing. If the test result
was positive, chemical sellers were trained to encourage clients
to purchase any of the three recommended artemisinin
combination therapies; amodiaquine-artesunate,
arthemeter-lumefantrine, or dihydroartemisinine-piperaquine.
Clients with a negative test were recommended to be referred
to a nearby health facility or a facility of their choice. Clients
who refused consent for a rapid diagnostic test received
presumptive treatment (current practice), and reasons for the
refusal of consent were documented. Blood slide results were
provided to all shops after three days; the results of the blood
slide were therefore not used by the chemical seller for initial
dispensing decisions. Patients who were slide-positive but who
had not been given an antimalarial in the chemical shop were
contacted within 24 hours and requested to return to the chemical
shop for an antimalarial. Follow-up was carried out on day 28
after the visit to the shop for all research slide-positive patients
to determine the clinical course and outcome of the illness and
care seeking behaviour after the visit to the chemical seller.
Randomization and registration
Communities were allocated to intervention or control by a
process of restricted randomisation to ensure balance in
covariates expected to be important correlates of the primary
outcome.37 38 Because of the differing number of shops in each
community, the balance was restricted to a difference of two in
the number of chemical shops per arm, the same number of
communities containing only one shop per arm, and amaximum
relative difference of 20% in the average number of cases per
day. Randomisation used a programwritten in R (version 2.14.2)
by a statistician not otherwise involved in the study. All
chemical sellers from shops assigned to each arm were invited
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to a meeting with the study team, informed about their
assignment, and enrolled into their study arm. Following this,
community sensitization meetings and durbars (a large
community meeting usually hosted by the traditional leaders of
the community during which issues important to the community
are discussed and consensus reached) were carried out to explain
the intervention to community members.
Those preparing and reading the blood slides were blind to the
study allocation and rapid diagnostic test result.
Permission was given by the Ghana Pharmacy Council for
chemical shop involvement. The trial received ethical clearance
from the Ethical ReviewCommittee of the GhanaHealth Service
and the ethics committee of the London School of Hygiene &
Tropical Medicine. It was registered on ClinicalTrials.gov
NCT01907672 before July 2011, although, because of a
technical misunderstanding, there was a delay in releasing the
protocol until September after trial start. (Formal release of the
protocol was after randomization but before any outcome data
were collected or analyzed, and no major changes were made
between the attempt to register the study and the date when
registration was complete.)
Statistical methods
After sample size calculations, the aim was for 24 communities
(12 per arm) to be included. Calculations were conducted to
determine a trial size sufficient to detect a 25% relative reduction
in the primary outcome from 60% in the control arm among
adults and 50% among children. Using methods for cluster
randomised trials and assuming a coefficient of variation
between clusters of 0.2, 80 adults and 114 children per
community were required to detect the specified reductions with
80% power at the 5% significance level.39
Data were double entered and validated using Epidata 6.1, and
analyzed using STATA version 12.0 (STATA Corporation,
College Station, Texas). The effect of the intervention was
analyzed using published methods suitable for cluster
randomized trials with fewer than 20 clusters per arm.38 39 The
observed proportion with the primary outcome was calculated
for each community (cluster). Within each arm, a weighted
average of the cluster proportions was taken with weights
provided by the sample size for each cluster, to give the
prevalence of the primary outcome in each arm. Due to the
skewness in the distribution of the cluster proportions, a log
transformation was applied and the mean of the log-proportions
over clusters (log of the geometric mean) was estimated in each
arm. The unadjusted risk ratio was then computed from
exponentiation of the log of the ratio of these geometric means.
The pooled variance of the log-proportions over clusters within
each arm was calculated and used to obtain 95% confidence
intervals and carry out formal hypothesis testing using a t test
on the logarithm of the risk ratio. Adjustment for covariates was
made by firstly fitting a standard logistic regression model to
the individual-level data, including terms for the covariates of
interest, but excluding the intervention effect. From the fitted
model, the expected number of events in each cluster was
computed. The ratio of the observed to expected number of
events in each cluster was used to calculate cluster-specific ratio
residuals. The next stage of analysis was to compare the
residuals between study arms using the above methods for
estimating the risk ratios and 95% confidence intervals as well
as hypothesis testing with the residuals replacing cluster-level
proportions. Analysis by age group and analyses of secondary
outcomes were conducted using the same methods.
Results
Figure 1⇓ shows the trial profile. The trial was conducted from
August 2011 to January 2013; last recruitment was 7 December
2012. Of the 4748 clients (2719 intervention, 2029 controls)
enrolled in the study, 4603 (97%) were included in the analysis
(fig 1) with 145 (44 negative rapid diagnostic test result, 34
positive rapid diagnostic test result, 67 controls) not assessable
because of haemolysed or clotted blood sample for the research
slide. The study was unable to achieve the planned sample size
specifically for the subgroup of children because of difficulties
in recruiting this age group at the chemical sellers. Communities
in both arms were similar (table 1⇓), although control arm sellers
were more likely to have had formal training in medicine
dispensing.
Treatment based on research slide results
Of 4603 clients who had research blood slide results, 1854/2641
(70%) in the intervention arm and 1570/1962 (80%) in the
control arm had a negative slide reading (no malaria). The
proportion of clients negative for malaria by blood slide who
received an antimalarial (artemisinin combination therapy or
other antimalarial) was significantly lower in the intervention
arm (590/1854, 32%) than the control arm (1378/1570, 88%)
(P<0.0001); the adjusted risk ratio was 0.41 (95% confidence
interval 0.29 to 0.58) (table 2⇓). Similar results were observed
when the analysis was conducted separately in children and
adults (table 2). In both study arms, among slide-negative clients
who received an antimalarial, a high proportion of the
antimalarials were artemisinin combination therapy; 1285/1378
(93%) in the control arm and 557/590 (94%) in the intervention
arm.
Rapid diagnostic tests did not lead either to a reduction or
increase in true malaria cases getting an effective antimalarial.
Of those who were slide-positive 690/787 (88%) in the
intervention arm and 347/392 (89%) in the control arm received
an artemisinin combination therapy (adjusted risk ratio 0.96
(0.84 to 1.09)).
Overall, 737 out of 3424 (21.5%) of all slide-negative clients
received an analgesic or non-steroidal anti-inflammatory drug
(NSAID) without an antimalarial or antibiotic, while 579 of
them received no medicine. Among all the 1179 slide-positive
clients, 23 (1.9%) received analgesics while 17 (1.4%) received
no medicine. Among slide-negative clients, 629/1854 (33.9%)
in the intervention arm and 108/1570 (6.9%) in the control arm
received an analgesic, suggesting that shopkeepers switched
appropriately from selling antimalarials to selling analgesics or
antipyretics to clients with non-severe illness and a negative
rapid diagnostic test result (fig 2⇓).
The secondary outcome of “appropriate malaria treatment”
differed between clients attending shops in communities in the
rapid diagnostic test arm (74%) compared with clients in the
control arm (27%); adlusted risk ratio 2.39 (1.69 to 3.39). This
composite indicator comprised clients with a positive blood
slide who received an artemisinin combination therapy and
clients with a negative slide who did not receive an artemisinin
combination therapy or other antimalarial. There was no
evidence of a difference between the arms in the former but
strong evidence of an increase in the latter (adjusted risk ratio
5.28 (2.5 to 10.77)). No clients with a positive slide result and
only seven with a negative slide reading received antibiotics,
which chemical sellers are not allowed to dispense in Ghana
(table 2⇓).
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Treatment on the basis of rapid diagnostic
test results
All 2719 clients visiting shops in intervention communities were
tested for malaria with rapid diagnostic tests. Of these, 1368
(50.3%) were reported negative, and 1351 (49.7%) were
positive. Treatment was in good agreement with the rapid
diagnostic test result, as recorded by chemical sellers. Among
those whowere reported negative for malaria by rapid diagnostic
test, only 38 (3%) received an artemisinin combination therapy
or other antimalarial, while 656 (48%) received an analgesic
and eight (0.6%) received an antibiotic. Overall, 570/1368 (42%)
clients with a negative rapid diagnostic test received no
medicine. Among clients with a positive rapid diagnostic test,
1344/1351 (99.5%) received an antimalarial. Only five (0.4%)
received no medicine while two (0.2%) received an analgesic
(fig 3⇓).
Sensitivity and specificity of rapid diagnostic
tests under operational conditions
Of the 2641 clients in the rapid diagnostic test arm who had a
valid research blood slide result, 29 who tested negative by
rapid diagnostic test were found to be positive by research slide
(table 3⇓). The operational sensitivity of rapid diagnostic tests
as used by chemical sellers was therefore 96% and specificity
was 70% judged against the gold standard of double-read
research slides. There was significant variation between
chemical shops in terms of apparent specificity. Sensitivity and
specificity of the rapid diagnostic test were calculated by shop,
restricted to those shops that enrolled more than 100 clients.
Sensitivity ranged from 98% to 100%, suggesting that all shops
were able to identify true cases. Most shops had specificity from
73% to 98%, but two had a specificity of 30% and 31% and one
of 52%, despite the sellers having successfully completed
training, raising the possibility that they were reporting positive
rapid diagnostic tests to justify sales of antimalarials.
Follow-up, referral, and safety
There was no evidence that introducing rapid diagnostic tests
led to major negative outcomes because true malaria cases were
missed. Of 1179 clients with a positive slide reading, 1076
(91.3%) were successfully followed up (670 intervention arm,
406 control) on day 28 after diagnosis, with missing data for
five. Of these, 95.3% (1021/1071) completed the treatment they
were sold by the chemical seller. There was no significant
difference between the two study arms with regards to client
completion of medication on follow-up (P=0.34). Five of them
(0.5%) did not receive any medicines from the chemical seller,
while 4.2% (45/1071) admitted not completing their
medications, of whom 34/45 did not because they felt better.
Only four stopped taking their medications because of side
effects.
Less than 1.5% (13/1071) of all the slide-positive clients
followed up admitted to being referred to another health facility
after their visit to the chemical seller, but significantly more of
these were from the rapid diagnostic test arm (P=0.024). None
of the clients who were followed up during the study period
died. One adult female client died after the study ended; the
death was not linked to the illness presented at the chemical
shop nor the treatment given.
Of 1368 clients, 1088 (80%) who tested negative with the rapid
diagnostic test were referred to the formal healthcare sector,
compared with only one client in the control arm. These were
contacted by phone to find out whether the referral was
completed. Of the 1088, 248 recalled being referred, 154 (62%)
reported that they went to the referral facility, while 94 (38%)
admitted to not going as they had been requested, and 54 said
they did not go because they felt better.
Mystery client and 133 other chemical seller-client interaction
observations in the intervention shops showed that chemical
sellers adhered largely to safety instructions for handling sharps.
For all 18 safety indicators assessed, the chemical sellers
performed well. The range was between 87.2% and 100%. The
lowest indicator was the proportion of chemical sellers who
discarded the lancet immediately into the sharps bin, which was
87.2% (116/133). Waste material from both bins was disposed
of regularly in the incinerators of the nearest public sector health
centre through a prior arrangement.
Discussion
Reducing overuse of antimalarials in the private sector is a
public health priority. Most people with malaria or febrile
symptoms, the commonest syndrome for severe illness in West
Africa, are treated in the private drug retail sector, but the effect
of introducing malaria diagnostics to this sector has been little
studied. There has been considerable debate on whether to
introduce rapid diagnostic tests into the private drug retail sector,
but with limited current evidence of impact or safety. The
incentives for drug shops (which want to sell drugs) are
completely different than for clinicians, and turning shops into
diagnostic centers for the most common acute condition (febrile
illness) has significant policy implications. Despite this, pressure
to introduce rapid diagnostic tests has been strong. For example,
the Public Accounts Committee of the UK parliament
recommended in 2013: “The [UK Government] should extend
its support for rapid diagnostic tests to the private drug retail
sector on a national or regional scale. to seize the unquestionable
benefits this would bring.”40
This trial showed that introducing rapid diagnostic testing for
malaria in chemical shops, the major private providers to poorer
patients in Ghana, to guide dispensing practice of chemical
sellers had a substantial impact on the dispensing of
antimalarials. There was no change in prescribing artemisinin
combination therapys to true malaria cases, but a significant
reduction in dispensing antimalarials of all types, and artemisinin
combination therapy specifically, was observed for
malaria-negative cases. Although there was still some
prescribing of antimalarials for test-negative clients, there was
a substantial reduction in the number of potentially serious
causes of infection which were being missed compared with
standard care. A study carried out in two shops in Nigeria had
similar findings.41 In the context of a country where antibiotics
cannot be sold by shops, sales were diverted to antipyretics by
the chemical sellers. No safety concerns were identified as a
result of introducing rapid diagnostic tests after a short period
of training, whether in not treating malaria cases, unexpected
mortality, or sharps handling; this is an important issue in areas
where hepatitis B is common and HIV prevalence is non-trivial.
There was no evidence of reuse of lancets or improper disposal
of sharps that could pose a danger to the public. There was an
increase in appropriate referral of clients from the chemical
shop to the formal healthcare sector.
Attempts to increase the proportion of children with fever who
get antimalarials from the private drug retail sector such as the
Affordable Medicines Facility for malaria have often been
successful, but evidence of how to reduce overuse of
antimalarials in those without malaria in the private sector has
been lacking.42 Despite our not achieving the target sample size
for the subgroup of children, the large effect estimates, small P
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h1019 doi: 10.1136/bmj.h1019 (Published 4 March 2015) Page 5 of 13
RESEARCH
values, andmoderately narrow 95% confidence intervals provide
evidence that an intervention effect exists and has been estimated
with reasonable precision in this setting. There is now a wide
body of literature on the effects of introducing rapid diagnostic
tests in the formal health sector and community workers in
Africa, albeit mainly from East Africa, and this has generally
shown that introducing rapid diagnostic tests after a short period
of training (like that provided here) is not sufficient to change
behavior of healthcare workers.43 More prolonged training and
ongoing supervision have generally been needed to achieve
good results, probably because malaria treatment practices are
driven by ingrained behaviours with multiple drivers44 45 in both
providers and clients,46 but when undertaken is successful.47Our
study in Ghana demonstrates a more rapid change in behavior
among shopkeepers when rapid diagnostic tests were first
introduced than that found among health staff in the same
setting. Health workers, particularly in a health facility where
testing for malaria with microscopy was known, still prescribed
antimalarials for a high proportion of test-negative patients.27
Clients visiting chemical shops in the intervention arm with
complaints of fever were three times more likely to receive
appropriate treatment for malaria fever than those visiting shops
where no rapid diagnostic test testing was being done.
There is evidence from several settings that rapid diagnostic
tests for malaria are not widely available in the private sector,
but that in principle they are acceptable to clients and
caregivers.48 49 Although this study lends good support to the
idea that rapid diagnostic tests can be introduced to the private
drug retail sector and be both effective and safe, three caveats
should be borne in mind. The first is the obvious one relevant
to all trials; results found under trial conditions, even relatively
operational trials such as this, are generally better than those
found in subsequent operational practice. The second is that in
this trial rapid diagnostic tests were introduced free. This
establishes the principle that rapid diagnostic tests can be well
used by shopkeepers if they are introduced without cost, such
as by the Global Fund, but the financial incentives will change
if the shopkeeper or client is paying for the test, and this could
change behavior. How much rapid diagnostic tests are sold for
is likely to influence uptake.50 The third is that chemical sellers
are not supposed to prescribe most antibiotics in Ghana
(although a few do), so one of the major risks of introducing
rapid diagnostic tests in some other countries—that they lead
to a switch from overuse of antimalarials to overuse of
antibiotics where they are freely sold—was not tested here; sales
were diverted almost exclusively to antipyretics or analgesics.
Not using antibiotics seems to be safe in children with a negative
rapid diagnostic test and without signs of severity; bacteremia
rates are low in outpatient settings except in children <1 year
old.51 Overprescription of antimalarials and the possible effects
of rapid diagnostic tests in Ghana in the private drug retail sector
is probably relevant to other settings.52 53 There is the possibility
that clients who are refused an antimalarial because of a negative
rapid diagnostic test may go to another shop to get one, but
follow-up data suggest this is rare (data not shown).
Anthropological data from other countries suggest patients want
a diagnosis they trust, not a specific drug.54 There is the risk that
shopkeepers changed their behaviour because blood samples
for slides were being taken, but this was true in both trial arms
and we think it unlikely that the large effect difference seen
between arms is fully explained by this.
The major problem of overprescription of antimalarials to
malaria-negative patients occurs in both the public and the
private sector, but the private sector sees the majority of patients
in Ghana. As the incidence of malaria drops in many settings,
the importance of targeting of antimalarials to those who need
them will increase. Considerable advances have been achieved
in formal public sector settings by the use of rapid diagnostic
tests. However, since most patients with fever and malaria are
treated before they get to the formal sector, ensuring best
targeting of antimalarials in the places such as shops where
patients, and especially rural poorer patients, go, is essential.
This study supports the idea that introduction of rapid diagnostic
tests in the private drug retail sector with a realistic training
package has the potential to be safe and effective.
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Tables
Table 1| Baseline characteristics of the study population by treatment arm. Values are numbers (percentages) unless stated otherwise
Control armRDT arm
(n=11)(n=12)Cluster level
2 (1–5)2 (1–5)Median (range) No of shops per cluster
213 (51–231)214 (17–572)Median (range) No of clients per cluster
Location:
00Urban only
3 (27)1 (8)Rural only
8 (73)11 (92)Both
(n=24)(n=27)Shop level
No of sellers per shop:
23 (96)26 (96)1-3
1 (4)1 (4)4-6
Regular seller:
14 (58)12 (44)Owner
10 (42)14 (52)Employee/assistant
0 (0)1 (4)Family
Education level of respondent:
0 (0)1 (4)Primary
18 (75)20 (74)Secondary
6 (25)6 (22)Tertiary
Formal training in medicine dispensing*:
6 (25)11 (41)No
18 (75)16 (59)Yes
Refresher training in past 6 months*:
6 (25)15 (56)No
18 (75)12 (44)Yes
Reported average No of clients per day:
8 (33)6 (22)<20
5 (21)7 (26)21-30
11 (46)14 (52)≥30
(n=2029)(n=2719)Client level
19 (6–32)15 (6–29)Median (IQR) age (years)
Age group:
390 (19)534 (20)<5 years
458 (23)719 (26)5-12 years
1181 (58)1466 (54)≥ 13 years
Sex:
997 (49)1343 (49)Male
1032 (51)1376 (51)Female
Community of residence:
730 (36)1198 (44)Urban
1299 (64)1521 (56)Rural
RDT=Rapid diagnostic test for malaria.
*Formal training refers to a 1 year training in medicine dispensing. Refresher training refers to training lasting from half a day to a maximum of three days usually
organized by the Pharmacy Council (the regulatory body), pharmaceutical companies, or other health agencies in specific subject areas.
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Table 2| Crude and adjusted treatment outcomes based on research slide result, by study arm
k
statistic
Adjusted results†Crude results*Intervention (RDT) armControl (no RDT) arm
P value
Risk ratio
(95% CI)P value
Risk ratio
(95% CI)
Prevalence
(%) among
clients
No of
clusters
Prevalence
(%) among
clients
No of
clusters
Primary outcome: slide result negative, client receives antimalarial‡
0.52<0.00010.41 (0.29 to
0.58)
<0.00010.34 (0.26 to
0.44)
590/1854 (32)121378/1570
(88)
11All clients
0.55<0.00010.40 (0.28 to
0.56)
<0.00010.33 (0.25 to
0.43)
334/1179 (28)12853/1013 (84)11Adults
0.450.0060.52 (0.36 to
0.74)
<0.00010.40 (0.29 to
0.56)
256/675 (38)12525/557 (94)11Children
Secondary outcomes
—<0.00012.39 (1.69 to
3.39)
<0.00012.86 (2.24 to
3.63)
1954/2641
(74)
12539/1962 (27)11Appropriate
treatment§
—0.470.96 (0.84 to
1.09)
0.420.94 (0.81 to
1.09)
690/787 (88)12347/392 (89)11ACT to
slide-positive
client¶
—<0.00015.28 (2.59 to
10.77)
<0.00015.94 (3.32 to
10.65)
1264/1854
(68)
12192/1570 (12)11No
antimalarial to
slide-negative
client
—————6/1854 (0.3)121/1570 (0.1)11Antibiotic to
slide-negative
client
—0.0133.46 (1.64 to
7.32)
0.0044.29 (2.09 to
8.84)
629/1854 (34)12108/1570 (7)11Analgesic or
antipyretic to
slide-negative
client
RDT=rapid diagnostic test for malaria. ACT=artemisinin combination therapy
*Adjusted for clustering, based on geometric mean of cluster summaries.
†Adjusted for clustering, age, sex, number of clients per cluster, number of shops per cluster, and characteristics of sellers (including whether they were the regular
seller and had formal training or refresher training in the previous six months).
‡Receiving an ACT or other antimalarial. Restricting the outcome to ACT only provides similar results; 1285 (82%) in the control arm; 557 (30%) in the RDT arm;
adjusted risk ratio 0.37 (95% CI 0.28 to 0.51), P<0.0001.
§Appropriate treatment defined as slide-positive client receiving an ACT or slide-negative client not receiving an antimalarial.
¶Among the 45 slide-positive clients in the control arm not receiving an ACT, 22 (49%) received other antimalarial, 8 (18%) received analgesic, 5 (11%) received
no medicines, and 10 (22%) received other medicines. In the RDT arm, 70/97 (72%) slide-positive clients not receiving an ACT received other antimalarial, 15
(15%) received analgesic, and 12 (12%) received no medicines.
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Table 3| Comparative results of the rapid diagnostic test (RDT) as used by chemical sellers and research blood slide results
RDT results
Slide results TotalNegativePositive
78729 (false negative)758Positive
18541295559 (false positive)Negative
784434Inadequate sample
271913681351Total
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Figures
Fig 1 Trial profile: rapid diagnostic test versus normal practice in Licensed Chemical shops
Fig 2 Medicines dispensed by chemical sellers with or without a rapid diagnostic test (RDT) for malaria, by the subsequent
blood slide results (not available to chemical seller to guide dispensing)
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Fig 3 Medicines dispensed by chemical sellers based on rapid diagnostic test (RDT) for malaria
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